Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Share :
Published: 4 Jun 2022
Views: 56
Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Jeanne Tie announces phase II of the randomised-controlled DYNAMIC trial.

She discusses that eligible patients of the trail had resected stage II colon cancer and were suitable for adjuvant CT. Patients were randomly assigned 2:1 to ctDNA-guided management or standard management (clinician-guided based on conventional criteria), after stratification for T stage.

Dr Tie continues on to state the primary efficacy endpoint was non-inferiority in RFS rate at 2 years. A key secondary endpoint was adjuvant CT use. The target sample size of 450 provided 80% power with 95% confidence to confirm non-inferiority between the two arms with a margin of 8.5%.

She concludes by explaining the results of the trial The low recurrence rate in ctDNA-positive patients who received chemotherapy suggests a survival benefit from adjuvant therapy. ctDNA-negative patients are unlikely to benefit from chemotherapy.

Watch the interview here

Read the article here